Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced that Mark Emalfarb, Chief Executive Officer, will present at the 2025 World Vaccine Congress in Washington, D.C.
World Vaccine Congress | Washington, D.C.
April 22–24, 2025
Presentation: Wednesday, April 23, 2025 | 12:40 PM–1:10 PM
Track: Influenza & Respiratory | Room 202A
Topic: C1 Platform: The Urgent Need for Smarter Biomanufacturing – A Call to Action on Avian Influenza (H5N1) & Future Pandemics
During the presentation, Mr. Emalfarb will provide an overview of recent preclinical research utilizing Dyadic’s proprietary C1 expression platform, including data related to the production of non-mRNA antigens and reagents for vaccine production.
“We are excited to share the latest pre-clinical data from multiple studies demonstrating that Dyadic’s proprietary C1 platform enables the production of non-mRNA antigens that elicit high neutralizing antibodies,” said Mr. Emalfarb. “Leveraging our C1 platform, we aim to enable rapid, cost-effective production of antigens, reagents and cell culture media products to address significant global health challenges, including avian influenza and future pandemics, through scalable and efficient biomanufacturing to meet the growing demand for rapid-response vaccines and therapeutics, paving the way for a more resilient global health infrastructure.”
Dyadic’s management team will be available for meetings throughout the conference.